FDA Approves IND and Grants Fast Track Designation for CBI-1214 T-Cell Engager in Colorectal Cancer
核心洞察
The FDA has approved an investigational new drug application and granted fast track designation for CBI-1214 (搜索), a T-cell engager targeting LY6G6D (搜索) for colorectal cancer (搜索) treatment.
CBI-1214 (搜索) specifically targets microsatellite stable and microsatellite instability-low colorectal cancer (搜索) subtypes, representing the vast majority of patients with significant unmet medical needs.
Cartography Biosciences (搜索) plans to initiate a Phase I clinical trial in the first quarter of 2026, leveraging their proprietary ATLAS and SUMMIT discovery platforms.
The US FDA has approved an investigational new drug (IND) application and granted fast track designation (FTD) for CBI-1214 (搜索), a T-cell engager being developed by Cartography Biosciences (搜索) for the treatment of patients with colorectal cancer (搜索). This dual regulatory milestone enables the company to initiate a Phase I clinical trial, anticipated to begin in the first quarter of 2026.
Targeting an Emerging Tumor Antigen
CBI-1214 (搜索) is a T-cell engager molecule that targets LY6G6D (搜索), an emerging and highly specific tumor antigen for treating patients with colorectal cancer (搜索). The target demonstrates minimal expression on healthy cells but is uniquely expressed within the microsatellite stable (MSS) and microsatellite instability-low (MSI-L) subtypes of colorectal cancer, which represent the vast majority of CRC patients and remain a major area of unmet medical need.
"This IND approval allows us to advance CBI-1214 (搜索), our novel T-cell engager, rapidly into clinical development," said Dirk Nagorsen, MD, chief medical officer of Cartography. "The Fast Track designation further validates the significant unmet need we are targeting in CRC and the potential impact of our approach. We look forward to expeditiously advancing our Phase I trial."
Addressing Significant Unmet Medical Need
Fast track designation is designed to facilitate the development and expedited review of drugs that treat serious conditions and fill an unmet medical need. This regulatory status underscores the potential of CBI-1214 (搜索) and the urgent, unmet need among patients with colorectal cancer (搜索).
Colorectal cancer (搜索) is the third most common cancer diagnosed in both men and women in the United States, and the second leading cause of cancer-related deaths globally. According to the American Cancer Society, an estimated 153,020 new cases of colorectal cancer are diagnosed annually in the U.S., leading to approximately 52,550 deaths. Despite advances in treatment, many patients face significant challenges, particularly in advanced stages, highlighting the urgent need for innovative and more effective therapeutic options.
Platform-Driven Drug Discovery
CBI-1214 (搜索) has protein engineering features that are specifically designed to optimize anti-tumor activity. The development of this T-cell engager represents validation of Cartography's proprietary discovery platforms.
"Receiving IND approval and Fast Track designation for CBI-1214 (搜索) represent two important steps forward for Cartography, further validation of our ATLAS and SUMMIT discovery platforms, a tribute to the hard work and ingenuity of our entire team and crucial progress toward addressing the unmet needs of colorectal cancer (搜索) patients," said Kevin Parker, CEO of Cartography Bio.
The ATLAS platform is a curated, fully integrated and proprietary set of single-cell RNA-based data and tissue repositories, containing 10 times the number of cells found in publicly available single-cell datasets. The SUMMIT platform focuses on multi-specific targeting to create synthetic targets. These platforms are powered by an industry-leading, fully integrated dataset spanning hundreds of thousands of cell states across the healthy body and large-scale profiling of individual cells from patient tumors.